In the latest trading session, 6.98 million Roivant Sciences Ltd (NASDAQ:ROIV) shares changed hands as the company’s beta touched 1.35. With the company’s most recent per share price at $10.80 changing hands around $0.72 or 7.14% at last look, the market valuation stands at $8.70B. ROIV’s current price is a discount, trading about -22.59% off its 52-week high of $13.24. The share price had its 52-week low at $6.92, which suggests the last value was 35.93% up since then. When we look at Roivant Sciences Ltd’s average trading volume, we note the 10-day average is 5.24 million shares, with the 3-month average coming to 5.30 million.
Roivant Sciences Ltd (NASDAQ:ROIV) trade information
Instantly ROIV is in green as seen in intraday trades today. With action 7.89%, the performance over the past five days has been green. The jump to weekly highs of 10.80 added 7.14% to the stock’s daily price. The company’s shares are showing year-to-date downside of -3.83%, with the 5-day performance at 7.89% in the green. However, in the 30-day time frame, Roivant Sciences Ltd (NASDAQ:ROIV) is -8.47% down. Looking at the short shares, we see there were 27.69 million shares sold at short interest cover period of 4.61 days.
Roivant Sciences Ltd (ROIV) estimates and forecasts
Data shows that the Roivant Sciences Ltd share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -12.97% over the past 6 months, a 34.81% in annual growth rate that is considerably higher than the industry average of 12.60%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2024 revenue estimates. The rating firms predict current quarter revenue for Roivant Sciences Ltd will fall -50.00%, while the growth in revenue is estimated to hit -10.50% for the next quarter. Year-over-year growth is forecast to reach 136.80% up from the last financial year.
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of $33.28 million. 8 analysts are of the opinion that Roivant Sciences Ltd’s revenue for the quarter ending Jun 2024 will be $47.61 million. The company’s revenue for the corresponding quarters a year ago was $27.38 million and $25.07 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 21.60%. The estimates for the next quarter sales put growth at 89.90%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 21.79%. The 2024 estimates are for Roivant Sciences Ltd earnings to increase by 558.07%.
Roivant Sciences Ltd (NASDAQ:ROIV)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 29.40% of Roivant Sciences Ltd shares while 62.06% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 87.90%. There are 62.06% institutions holding the Roivant Sciences Ltd stock share, with QVT Financial LP the top institutional holder. As of Jun 29, 2023, the company held 15.88% of the shares, roughly 122.54 million ROIV shares worth $1.24 billion.
SB Investment Advisers (UK) LTD holds the second largest percentage of outstanding shares, with 10.76% or 83.03 million shares worth $836.96 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Aug 30, 2023 were Fidelity Growth Company Fund and Vanguard Specialized-Health Care Fund. With 10.3 million shares estimated at $119.14 million under it, the former controlled 1.33% of total outstanding shares. On the other hand, Vanguard Specialized-Health Care Fund held about 1.24% of the shares, roughly 9.57 million shares worth around $114.67 million.
